<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995133</url>
  </required_header>
  <id_info>
    <org_study_id>3946</org_study_id>
    <nct_id>NCT04995133</nct_id>
  </id_info>
  <brief_title>Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.</brief_title>
  <official_title>Pharmacokinetic/Pharmacodynamic Aspects of Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs and Receiving Continuous Renal Replacement Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colistin is an antibiotic active against several classes of multi-resistant gram-negative&#xD;
      bacteria; the drug should be used in high doses in patients on continuous renal replacement&#xD;
      therapy, since the drug is eliminated through the dialysis filter.&#xD;
&#xD;
      This is an Open-label, Phase 4, interventional, prospective, single-center pilot study aimed&#xD;
      to analyze the concentrations of colistin in plasma and ultrafiltrate by liquid&#xD;
      chromatography/mass spectrometry, in 20 critically ill patients admitted to intensive care&#xD;
      and suffering from severe infections by multi-resistant bacteria, who receive continuous&#xD;
      renal replacement therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>0-12 hours</time_frame>
    <description>Colistin A and B misuration in the plasma and in the pre-post filter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration</measure>
    <time_frame>0-12 hours</time_frame>
    <description>Colistin A and B misuration in the plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life</measure>
    <time_frame>0-12 hours</time_frame>
    <description>Colistin A and B misuration in the plasma</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hospital Infection</condition>
  <condition>Multi-antibiotic Resistance</condition>
  <condition>Critically Ill</condition>
  <arm_group>
    <arm_group_label>Colistin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of 6.75 x 106 Units Colistin for 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistin</intervention_name>
    <description>intravenous administration</description>
    <arm_group_label>Colistin Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infection where the involvement of MDR germs is documented or highly probable&#xD;
&#xD;
          -  Continuous renal replacement therapy&#xD;
&#xD;
          -  Acute renal failure, stage III of the 2012 KDIGO classification&#xD;
&#xD;
          -  Half-life of the continuous renal replacement therapy filter less than 48 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  State of pregnancy or breastfeeding, or patients expecting to conceive children within&#xD;
             the projected duration of the study, starting with the screening through 30 days after&#xD;
             the last dose of IMP treatment&#xD;
&#xD;
          -  Patients with a positive urine pregnancy test within 72 hours prior to study drug&#xD;
             treatment. If the urine test is positive or cannot be confirmed as negative, a serum&#xD;
             pregnancy test will be required. In the event that 72 hours have elapsed between the&#xD;
             screening pregnancy test and the first dose of study treatment, another pregnancy test&#xD;
             (urine or serum) must be performed and must be negative in order for subject to start&#xD;
             receiving study medication&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Refusal of informed consent&#xD;
&#xD;
          -  Known hypersensitivity to polymyxins and to excipients&#xD;
&#xD;
          -  Clinical condition with high probability of death, according to Symplified Acute&#xD;
             Physiology Score (SAPS II)&#xD;
&#xD;
          -  Partial maintenance of renal function, defined by stages I and II of the 2012 KDIGO&#xD;
             classification.&#xD;
&#xD;
          -  Renal replacement therapy filter other than AN69 ST 150&#xD;
&#xD;
          -  Prior systemic treatments with any investigational agents within 4 weeks prior to the&#xD;
             inclusion in the trial&#xD;
&#xD;
          -  Any other clinical condition that, in the opinion of the investigator, makes the&#xD;
             patient unfit for the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondazione Policlinico A.Gemelli IRCSS</name>
      <address>
        <city>Roma</city>
        <state>Italia</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margherita Zona</last_name>
      <phone>+390630155701</phone>
      <email>margherita.zona@policlinicogemelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</investigator_affiliation>
    <investigator_full_name>NAVARRA PIERLUIGI</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Colistin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

